Commonwealth Equity Services
TVTX icon

Commonwealth Equity Services’s Travere Therapeutics TVTX Stock Holding History

Commonwealth Equity Services’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Sell
6,539
-2,170
-25% -$96.2K ﹤0.01% 3572
2026
Q1 		$259K Buy
+8,709
New +$260K ﹤0.01% 3759

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services's TVTX Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Travere Therapeutics (TVTX) stake by 25% in Q2 2026, selling an estimated $96.2K and leaving 6,539 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #3572.

Commonwealth Equity Services first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Commonwealth Equity Services held 6,539 shares of Travere Therapeutics worth $371K as of Q2 2026.
  • Commonwealth Equity Services sold 2,170 Travere Therapeutics shares in Q2 2026, an estimated $96.2K.
  • Travere Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #3572 holding.
  • Commonwealth Equity Services first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.